Abstract:The frequent outbreak of respiratory infectious diseases such as influenza and pulmonary tuberculosis calls for new immunization strategies with high effectiveness. Nasal immunization is one of the most potential methods to prevent the diseases infected through the respiratory tract. In this study, we designed a water-soluble system based on antigen/N-trimethylaminoethylmethacrylate chitosan conjugates for nasal immunization. N-trimethylaminoethylmethacrylate chitosan (TMC) was synthesized by free radical polymerization of chitosan and N-trimethylaminoethylmethacrylate chloride and identified by (1)H NMR and FT-IR. Thiolated ovalbumin (OVA) was covalently conjugated to maleimide modified TMC with high conjugation efficiency. OVA conjugated TMC (OVA-TMC) significantly increased uptake of OVA by Raw 264.7 cells, which was 2.38 times higher than that of OVA/TMC physical mixture (OVA+TMC) at 4h. After nasal administration, OVA-TMC showed higher transport efficiency to superficial and deep cervical lymph nodes than OVA+TMC or OVA alone. Balb/C mice were intranasally given with OVA-TMC three times at 2-week internals to evaluate the immunological effect. The serum IgG, IgG1 and IgG2a levels of the OVA-TMC group were 17.9-87.9 times higher than that of the OVA+TMC group and comparable to that of the intramuscular group. The secretory IgA levels in nasal wash and saliva of the OVA-TMC group were 5.2-7.1 times higher than that of the OVA+TMC group while the secretory IgA levels of the intramuscular alum-precipitated OVA group were not increased. After immunofluorescence staining of nasal cavity, IgA antibody secreting cells were mainly observed in the lamina propria regions and glands of nasal mucosa. OVA-TMC showed little toxicity to the nasal epithelia or cilia of rats after nasal administration for three consecutive days. These results demonstrated that antigen conjugated TMC can induce both systemic and mucosal immune responses after nasal administration and may serve as a convenient, safe and effective vaccine for preventing respiratory infectious diseases.

Development and Optimization of Chitosan Nanoparticle-Based Intranasal Vaccine Carrier

Studies on Protein Antigen/Chitosan Nanoparticles for Nasal Vaccine Delivery

Curdlan Sulfate-O-linked Quaternized Chitosan Nanoparticles: Potential Adjuvants to Improve the Immunogenicity of Exogenous Antigens Via Intranasal Vaccination.

[Applying Chitosan-Modified Nanoemulsion in Nasal Vaccine Delivery].

Preparation and Characterization of Curdlan-Chitosan Conjugate Nanoparticles As Mucosal Adjuvants for Intranasal Influenza H1n1 Subunit Vaccine

Preparation and immunological activity evaluation of an intranasal protein subunit vaccine against ancestral and mutant SARS-CoV-2 with curdlan sulfate/O-linked quaternized chitosan nanoparticles as carrier and adjuvant

Dry-powder form of chitosan nanospheres containing influenza virus and adjuvants for nasal immunization

Transmucosal Delivery of Nasal Nanovaccines Enhancing Mucosal and Systemic Immunity.

Pathogen-Mimicking Nanoparticles Based on Rigid Nanomaterials As an Efficient Subunit Vaccine Delivery System for Intranasal Immunization

Pathogen‐mimicking Nanoparticles Based on Rigid Nanomaterials as an Efficient Subunit Vaccine Delivery System for Intranasal Iimmunization

Preparation of Chitosan Nanoparticles as a Capable Carrier for Antigen Delivery and Antibody Production

Chitosan as a novel nasal delivery system for vaccines

Fabrication of chitosan-based emulsion as an adjuvant to enhance nasal mucosal immune responses

The Application of Chitosan-Based Nanocarrier for Oral Protein Drug/Vaccine Delivery

The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization.

Preparation and Evaluation of Antigen/n-Trimethylaminoethylmethacrylate Chitosan Conjugates for Nasal Immunization

Curdlan Sulfate/o-Linked Quaternized Chitosan Nanoparticles Acting As Potential Adjuvants Promote Multiple Arms of Immune Responses.

Chitosan Nanoparticles for Intranasal Drug Delivery

Antigen-conjugated N-trimethylaminoethylmethacrylate Chitosan Nanoparticles Induce Strong Immune Responses after Nasal Administration

Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects mice against nasopharyngeal colonization by Streptococcus pneumoniae.

Preparation and Optimization of Bovine Serum Albumin Nanoparticles as a Promising Gelling System for Enhanced Nasal Drug Administration